Ingrid Glimelius
Forskare vid Institutionen för immunologi, genetik och patologi, Experimentell och klinisk onkologi; Forskargrupp Ingrid Glimelius
- E-post:
- ingrid.glimelius[AT-tecken]igp.uu.se
- Mobiltelefon:
- 070-2253912
- Besöksadress:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala - Postadress:
- Akademiska sjukhuset, ingång 100/101
751 85 Uppsala
Kort presentation
Senior Consultant and Associate Professor at the Oncology Clinic, Uppsala University Hospital. I conduct both clinical trials and large register-based investigations with a specific focus on Mantle Cell Lymphoma.
I am also affiliated to the Clinical Epidemiology Unit, Karolinska Institutet.
I study etiology, prognosis and late-effects (childbearing) in patients burdened by lymphatic malignancies.
My research projects also cover many translational projects at the Pathology Department.
Akademiska meriter: Leg läk
Nyckelord: hodgkin lymphoma survivorship ovarian cancer testicular cancer childbirth after cancer mantle cell lymphoma cancer epidemiology
One of our patients talking about participation in a clinical trial regarding Mantle Cell Lymphoma: https://www.youtube.com/watch?v=df6stYjhWXM
https://www.medfarm.uu.se/vision/ Creating visons for the Medical Faculty Fall 2020
-
Att få livet tillbaka med hjälp av nya läkemedel
https://www.youtube.com/watch?v=df6stYjhWXM
En av patienterna berättar om deltagandet i en av de kliniska studier vi genomför
-
Vision Uppsala University
https://www.medfarm.uu.se/vision/
Här pratar jag om hur vi kommer fram till en ny vision för Uppsala Universitet
MD, Uppsala University 2001
PHD, Uppsala University 2009, Hodgkin lymphoma – an interplay between tumour cell and microenvironment
MD, specialist Internal Medicine 2011
MD, specialist Oncology 2013
Associate Professor in Oncology 2016
Good Clinical Practice, Investigator Site Personnel ICH-GCP 2017
Senior Consultant Oncology 2019
Hodgkin lymphoma
Hodgkin lymphoma affects young adults and is today a curable disease with intensive chemotherapy. In this article, published in Journal of Clinical Oncology, the childbearing potential in survivors after Hodgkin lymphoma have been investigated together with researcher at Karolinska Institutet Caroline Weibull. We show that in the absence of relapse, contemporarily treated women have an improved childbearing potential with calendar time and women treated today give birth to the same degree as matched comparators.
In a related publication in Journal of Clinical Oncology from 2016 we have earlier shown the safety of having children for female survivors, were there was no increased risk of relapse after a pregnancy
Weibull CE, Johansson ALV, Eloranta S, Smedby KE, Björkholm M, Lambert PC, Dickman PW, Glimelius I. J Clin Oncol. 2018 Jul 25:JCO2018783514. doi: 10.1200/JCO.2018.78.3514. [Epub ahead of print] PMID: 30044694
Pregnancy and the Risk of Relapse in Patients Diagnosed With Hodgkin Lymphoma.
Weibull CE, Eloranta S, Smedby K, Björkholm M, Kristinsson SY, Johansson AL, Dickman PW, Glimelius I. J Clin Oncol. 2016 Feb 1;34(4):337-44. doi: 10.1200/JCO.2015.63.3446. Epub 2015 Dec 14. PMID: 26668344
Mantle Cell Lymphoma
Mantle cell lymphoma is today one of the lymphomas with poor prognosis. I am national principal investigator in the ENRICH-trial (KFUE Akademiska Sjukhuset): A randomized phase III trial in elderly patients with randomization between Rituximab-Ibrutinib AND Rituximab-chemotherapy (Bendamustine or CHOP) with the aim to test if a chemotherapy free concept can improve survival. In addition I am local PI of the VALERIA trial in Uppsala testing Lenalidomide-Venetoclax and Rituximab for relapsed/refractory mantle cell lymphoma patients. In addition I am currently investigating the impact of associated diseases on the prognosis of Mantle Cell Lymphoma. PHD students interested in the field are welcome to contact me.
Pregnancy and the risk of cancer
In two recent articles published in International Journal of Cancer and a comprehensive review published in Journal of Internal Medicine the associations between pregnancies and later cancer risk in the mother is examined. In the first article we show that a full length pregnancy protects against epithelial ovarian cancer to a higher extent than a pregnancy resulting in preterm delivery. In the next article, we show a decreased risk of breast cancer for females experiencing high blood pressure prior to and during pregnancy. In the review we both illustrate and discuss different aspects of pregnancy and a later risk of several solid malignancies.
Sköld C, Bjørge T, Ekbom A, Engeland A, Gissler M, Grotmol T, Madanat-Harjuoja L, Gulbech Ording A, Stephansson O, Trabert B, Tretli S, Troisi R, Toft Sørensen H, Glimelius I.
Int J Cancer. 2018 May 8. doi: 10.1002/ijc.31581. [Epub ahead of print] PMID:29737528
Troisi R, Gulbech Ording A, Grotmol T, Glimelius I, Engeland A, Gissler M, Trabert B, Ekbom A, Madanat-Harjuoja L, Toft Sørensen H, Tretli S, Bjørge T.
Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31600. [Epub ahead of print] PMID: 29752724
Troisi R, Bjørge T, Gissler M, Grotmol T, Kitahara CM, Myrtveit Saether SM, Ording AG, Sköld C, Sørensen HT, Trabert B, Glimelius I.J Intern Med. 2018 May;283(5):430-445. doi: 10.1111/joim.12747. Epub 2018 Mar 25. PMID:29476569
Kontakta katalogansvarig vid den aktuella organisationen (institution eller motsv.) för att rätta ev. felaktigheter.
